Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of State-of-the-Art Exoskeleton Technology to Improve Mobility in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04587193
Recruitment Status : Not yet recruiting
First Posted : October 14, 2020
Last Update Posted : November 9, 2020
Sponsor:
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
The purpose of this study is to test the safety and efficacy of using of a portable exoskeleton for walking training in persons with Parkinson's disease that have gait mobility problems and/or postural instability.

Condition or disease Intervention/treatment Phase
Parkinson Disease Device: Robotic-assist gait training device Not Applicable

Detailed Description:
This is a feasibility study to examine a novel application of state-of-the-art robotic-assist gait training to improve mobility in people with Parkinson's disease (PD). The study will investigate the utility of the Keeogo® exoskeleton (a robotic-assist gait training device) for people with PD. The Keeogo® offers advantages of being lightweight and portable (for eventual home use) and is relatively quick to attach and remove. The aims here are to establish the safety of the Keeogo® for gait training in persons with PD and to preliminarily assess the potential efficacy of the Keeogo® for better balance control, gait mobility and fall reduction in persons with PD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Safety and Efficacy of State-of-the-Art Exoskeleton Technology to Improve Mobility in Parkinson's Disease
Estimated Study Start Date : January 2021
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PD participants
Subjects will participate in a total of 10 walking sessions, twice per week for 5 weeks, while wearing a robotic-assist gait training device. There will also be 3 additional visits for assessments at: baseline (up to 1 prior to treatment), post (1 week after last treatment), and final (4-6 weeks after last treatment).
Device: Robotic-assist gait training device
PD participants will walk while wearing a robotic-assist gait training device




Primary Outcome Measures :
  1. Safety of the portable exoskeleton [ Time Frame: At the end of treatment (5 weeks) ]
    Number of "prevented" or "near falls" requiring physical assistance by the investigative training team experienced by the participant during throughout the training.


Secondary Outcome Measures :
  1. Change in walking capacity [ Time Frame: Baseline, post treatment (5 weeks), 4-5 week follow up (up to 14 weeks) ]
    Walking capacity will be assessed using the 6-Minute Walking Test (6MWT) that assesses distance walked to determine aerobic capacity and endurance. Participants will be asked to walk as far as possible in 6 minutes and the total distance will be recorded.

  2. Change in freezing of gait (FOG) [ Time Frame: Baseline, post treatment (5 weeks), 4-5 week follow up (up to 14 weeks) ]
    FOG will be assessed using the 6MWT. FOG will be assess using 2 gait related questions on the Unified Parkinson's Disease Rating Scale (UPDRS). Scores are summed and range from 0 (normal) to 4 (very poor).

  3. Change in balance [ Time Frame: Baseline, post treatment (5 weeks), 4-5 week follow up (up to 14 weeks) ]
    The Berg Balance Scale (BBS) assesses balance via asking the participant to perform 14 functional activities. Ability to perform the functions is rated on a 5 point scale from 0 (unable) to 4 (able safety or with minimal aid). Scores range from 0 to 56 with higher scores indicating better balance.

  4. Change in motor symptoms [ Time Frame: Baseline, post treatment (5 weeks), 4-5 week follow up (up to 14 weeks) ]
    The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part IIIMDS-UPDRS, part III will be used to assess motor symptoms and fluctuations of Parkinson Disease (PD) This outcome measure will be used to report a change in PD motor symptoms from baseline. Scores range from 0 to 56 with higher scores indicating more symptoms.

  5. Change in quality of life (QOL) [ Time Frame: Baseline, post treatment (5 weeks), 4-5 week follow up (up to 14 weeks) ]
    Parkinson's Disease Questionnaire (PDQ39) is a 39 item self-report questionnaire assessing how often patients experience difficulties across the 8 quality of life dimensions of functioning and well-being. Items are scored from 0 (never) to 4 (always) and can be summed in the PDQ39 Summary Index with lower scores indicating better QOL.

  6. Change in Caregiver QOL [ Time Frame: Baseline, post treatment (5 weeks), 4-5 week follow up (up to 14 weeks) ]
    Participant's caregivers QOL will be assessed using the Parkinson's Disease Carer Questionnaire (PD-Carer), a 29 item measure of health related quality of life for use with carers of people with Parkinson's disease. Scores range from 0 (no problem at all) to 100 (worst level of problem).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Parkinson's Participant

  1. age 21 years or older,
  2. PD confirmed by a movement disorder specialist using UK Brain Bank Criteria,
  3. H&Y stage III, IV, or V.

Caregiver participant 1) Caregiver of PD participant and is willing to complete questionnaire

Exclusion Criteria:

Parkinson's Participant

  1. neurological, musculoskeletal, or other disorders unrelated to PD contributing to impairment of gait, stance, balance or coordination,
  2. history of implantable cardiac device or ablative surgery,
  3. moderate to severe cognitive impairment / dementia (Montreal Cognitive Assessment < 17/30),
  4. uncontrolled orthostatic hypotension,
  5. feeding tube or associated port placement (PEG/J-PEG),
  6. body height less than 5'1" or greater than 6'3" and
  7. body weight greater than 250 pounds.

Caregiver participant

1) Unwilling to complete questionnaire


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04587193


Contacts
Layout table for location contacts
Contact: Gina Blackwell, MPH 804-921-9990 Gina.Blackwell@vcuhealth.org
Contact: Robert Hand, PT, DPT Robert.Hand@vcuhealth.org

Locations
Layout table for location information
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
Investigators
Layout table for investigator information
Principal Investigator: Mark Baron, MD Virginia Commonwealth University Health System
Principal Investigator: Robert Hand, PT, DPT Virginia Commonwealth University Health System
Layout table for additonal information
Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT04587193    
Other Study ID Numbers: HM20020066
First Posted: October 14, 2020    Key Record Dates
Last Update Posted: November 9, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Virginia Commonwealth University:
Gait
Balance
Freezing
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases